20 Oct 20 | All | Celltrion | The American Journal of Managed Care reported a new study indicates Celltrion's rituximab biosimilar CT-P10 could lower costs and expand patient access to biologic therapy for primary Sjogren syndrome.

20 Oct 20 | EG | Sandoz | Daily News E...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags